Showing results (1111-1120 of 1,211) with videos related to
Sort By:
Pageof 122
European Heart Journal|August 27, 2022
Dapagliflozin for heart failure according to body mass index: the DELIVER trialCarly Adamson, Toru Kondo, Pardeep S Jhund, et al.European Journal of Heart Failure|December 12, 2018
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the AmericasPooja Dewan, Pardeep S Jhund, Li Shen, et al.American Heart Journal|April 2, 2025
Rationale and design of NUDGE-CKD: A nationwide randomized factorial trial of electronic nudges for increasing guideline-directed medical therapy in chronic kidney diseaseKristoffer Grundtvig Skaarup, Niklas Dyrby Johansen, Lisbet Brandi, et al.European Heart Journal|June 30, 2016
Geographic variations in the PARADIGM-HF heart failure trialSøren Lund Kristensen, Felipe Martinez, Pardeep S Jhund, et al.Journal of the American College of Cardiology|January 4, 2023
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Lubna Choudhury, et al.Journal of the American College of Cardiology|November 13, 2020
Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert PanelMitchell A Psotka, William T Abraham, Mona Fiuzat, et al.Circulation|October 12, 2020
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HFPardeep S Jhund, Scott D Solomon, Kieran F Docherty, et al.Nature Medicine|August 27, 2022
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVERPardeep S Jhund, Toru Kondo, Jawad H Butt, et al.JAMA Cardiology|January 22, 2025
Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid InfiltrationAldostefano Porcari, Yousuf Razvi, Francesco Cappelli, et al.Lancet (London, England)|September 2, 2020
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, et al.Pageof 122